[PRNewswire] BioLineRx Enters Co-Development Agreement with GenFleet to
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit of combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and chemotherapy in a second-line setting," said Qiang Lu [https://www.linkedin.com/in/qiang-lu-54271ab/ ], Chairman of GenFleet. "We believe that this combination could be beneficial to patients in a first-line setting as well, and we hope to confirm this in a randomized trial. We are thrilled to be partners with BioLineRx in the development of this late-stage clinical asset, and look forward to initiating this important trial as quickly as possible. Throughout this journey, MSQ team has demonstrated professionalism and dedication in helping both of our teams to reach the finish line in a timely fashion."
본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures
(NEW YORK, June 29, 2022 PRNewswire=연합뉴스) M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. [https://www.linkedin.com/company/biolinerx/ ] ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc. [https://www.linkedin.com/company/genfleet-therapeutics/ ], an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC").
Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China. This randomized controlled study will aim to evaluate the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care.
"This collaboration is based on the highly encouraging results from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1 and chemotherapy, which provide strong support for continued development in this very challenging disease. With its broad solid tumor oncology pipeline and highly experienced development team, we believe we have found an outstanding partner in GenFleet to execute a rigorously designed randomized Phase 2b trial," said Philip Serlin [https://www.linkedin.com/in/phil-serlin-00954ba/ ], CEO of BioLineRx. "The MSQ team helped to navigate through the complexity of cross-border transactions and secured this transaction by deploying their deep knowledge of the global market. We are highly impressed with MSQ's "thinking outside the box" approach and their expertise in deal structuring and negotiation."
"The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit of combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and chemotherapy in a second-line setting," said Qiang Lu [https://www.linkedin.com/in/qiang-lu-54271ab/ ], Chairman of GenFleet. "We believe that this combination could be beneficial to patients in a first-line setting as well, and we hope to confirm this in a randomized trial. We are thrilled to be partners with BioLineRx in the development of this late-stage clinical asset, and look forward to initiating this important trial as quickly as possible. Throughout this journey, MSQ team has demonstrated professionalism and dedication in helping both of our teams to reach the finish line in a timely fashion."
Echo Hindle-Yang [https://www.linkedin.com/404/ ], CEO of MSQ, reflects on the transaction, "This collaboration demonstrates another excellent example of global co-development, which leverages each company's regional expertise to accelerate the development of new treatments. We are excited to see the alliance between BioLineRx and Genfleet to pursue the treatment of PDAC, which has proven to be incredibly challenging. I am impressed by Phil's commitment to developing Motixafortide in PDAC which is also shared by GenFleet's Dr. Lu. With such a strong commitment from each team, we believe that patients will benefit from this collaboration. We are honored to move forward with this cross-border partnership, and help achieve future success.
About MSQ
M.S.Q. Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market.
info@msqventures.com
Logo - https://mma.prnewswire.com/media/1849947/MSQ_Ventures_Logo.jpg
MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. From understanding key segments of the China healthcare market to identifying and vetting the high potential counterparties to negotiating deals aimed at maximizing value creation, our team focuses on results, prioritizes efficiency to guide our clients through the entire process.
Source: MSQ Ventures
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 22대 첫 국회의장, 추미애·우원식 양자대결…조정식·정성호 경선 불출마(종합) | 연합뉴스
- 與비대위원에 유상범·전주혜·엄태영·김용태…"지역안배"(종합) | 연합뉴스
- 대통령실 "국정 3년차 정책 방향은 민생·대국민 소통" | 연합뉴스
- 의대증원 이번주 분수령…법원 기각하면 의대증원 확정 초읽기 | 연합뉴스
- 비 그치고 갠 일요일에 전국 황사…대구엔 황사위기경보(종합) | 연합뉴스
- 13대 최저임금위원회 구성 완료…공익위원 놓고 노동계 반발(종합) | 연합뉴스
- [르포] 하늘의 도깨비 '팬텀' 고별 국토순례…'후배 전투기' KF-21 동행 | 연합뉴스
- 최상목 "민주당 25만원 민생회복지원금 입법, 위헌 소지 있어"(종합) | 연합뉴스
- 與, 라인 사태에 "우리 국익·기업이익 반하는 행동 없도록 지원" | 연합뉴스
- "의대생 집단유급 막아야"…계절학기 확대·국시 접수 연기 요청 | 연합뉴스